Kirenia Perez
Overview
Explore the profile of Kirenia Perez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valdes-Zayas A, Gonzalez Z, Mulens V, Vega A, Perez K, Lorenzo-Luaces P, et al.
J Immunother
. 2017 Jun;
40(8):289-301.
PMID: 28604556
This study aimed to investigate the immunogenicity of a cancer vaccine consisting of the NeuGcGM3 ganglioside combined with the outer membrane protein complex of Neisseria meningitides to form very small...
2.
de la Torre A, Perez K, Vega A, Santiesteban E, Ruiz R, Hernandez L, et al.
Breast Cancer (Auckl)
. 2016 Feb;
10:5-11.
PMID: 26917965
NGcGM3 ganglioside is a tumor-specific antigen expressed in human breast tumors. The NGcGM3/VSSP vaccine, consisting in very small-sized proteoliposomes (VSSP) obtained by the incorporation of NGcGM3 into the outer membrane...
3.
Alfonso S, Valdes-Zayas A, Santiesteban E, Flores Y, Areces F, Hernandez M, et al.
Clin Cancer Res
. 2014 May;
20(14):3660-71.
PMID: 24788102
Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. This clinical trial was conducted to provide a preliminary estimate of efficacy and safety of racotumomab as switch maintenance...
4.
Perez K, Osorio M, Hernandez J, Carr A, Fernandez L
Hum Vaccin Immunother
. 2013 Feb;
9(6):1237-40.
PMID: 23442598
Gangliosides are glycosphingolipids that are present in the plasma membranes of vertebrates and are involved in multiple cellular processes. In the Center of Molecular Immunology an NGcGM3 ganglioside based vaccine...
5.
Osorio M, Gracia E, Reigosa E, Hernandez J, de la Torre A, Saurez G, et al.
Cancer Manag Res
. 2012 Oct;
4:341-5.
PMID: 23055778
NeuGc-containing gangliosides have been described in melanoma cells and are an attractive target for cancer immunotherapy because they are minimally or not expressed in normal human tissues. Melanoma patients treated...
6.
de la Torre A, Hernandez J, Ortiz R, Cepeda M, Perez K, Car A, et al.
Breast Cancer (Auckl)
. 2012 Oct;
6:151-7.
PMID: 23055739
Patients treated with vaccines based on NGlycolil gangliosides have showed benefit in progression free survival and overall survival. These molecules, which have been observed in breast cancer cells, are minimally...
7.
Rodriguez M, Rivero T, Del Castillo Bahi R, Muchuli C, Bilbao M, Neninger Vinageras E, et al.
Cancer Biol Ther
. 2010 May;
9(5):343-9.
PMID: 20448462
The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elevated levels of EGFR are associated with a shorter disease free survival and time...
8.
Alfonso S, Diaz R, de la Torre A, Santiesteban E, Aguirre F, Perez K, et al.
Cancer Biol Ther
. 2007 Dec;
6(12):1847-52.
PMID: 18075301
Conventional treatment of non-small cell lung cancer (NSCLC) has apparently reached a plateau of effectiveness in improving the survival of the patients. For that reason the search for new therapeutic...